SCHEMBL1497352

SCHEMBL1497352

COC(=O)c1ccc([N+](=O)[O-])c(OCCCNC(=O)OC(C)(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.49
PELP1 Q8IZL8 1/20 0.49
ALDH1A1 P00352 5/20 0.47
CA12 O43570 5/20 0.46
CA1 P00915 5/20 0.46
CA2 P00918 5/20 0.46
CA9 Q16790 5/20 0.46
VCAM1 P19320 1/20 0.45
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
MGLL Q99685 2/20 0.43
BRD4 O60885 1/20 0.42
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23628904 0.97 AR (0.50) ARPELP1ALDH1A1CA12CA1
SCHEMBL6260157 0.85 MAPT (0.53) ALDH1A1CA12CA1CA2CA9
SCHEMBL5962704 0.83 MGLL (0.58) ALDH1A1CA12CA1CA2CA9
SCHEMBL1979111 0.83 ALDH1A1 (0.47) ALDH1A1VCAM1HPGDNPSR1LMNA
SCHEMBL6261344 0.82 ALDH1A1 (0.51) ALDH1A1CA12CA1CA2CA9
SCHEMBL4832898 0.82 ALDH1A1 (0.56) ALDH1A1CA12CA1CA2CA9
SCHEMBL30158929 0.82 CA12 (0.41) ALDH1A1CA12CA1CA2CA9
SCHEMBL29155054 0.82 BRD4 (0.48) ALDH1A1VCAM1KDM4ELMNAMGLL
SCHEMBL23971082 0.82 CA12 (0.41) ALDH1A1CA12CA1CA2CA9
SCHEMBL30163681 0.82 BRD4 (0.48) ALDH1A1VCAM1KDM4ELMNAMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2475375-A2 PI3 KINASE INHIBITORS AND USES THEREOF Avila Therapeutics, Inc. (US) 2012-07-18 EP disclosed
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-09-22 US disclosed
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-09-22 US disclosed
WO-2011031896-A2 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-03-17 WO disclosed
WO-2011031896-A2 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF PIK3CA, PIK3CB, PIK3C2B AR 2815/4885PELP1 3788/4885ALDH1A1 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.